| Neuman, Heather |
| Completed | 1 | 10 | US | SLN mapping using technetium-99m +/- isosulfan blue dye, SLN mapping with ICG fluorescence using the Asimov Platform | University of Wisconsin, Madison, OnLume Inc., National Cancer Institute (NCI) | Breast Cancer | 06/23 | 06/23 | | |
| Active, not recruiting | N/A | 627 | US, RoW | Usual Care, Web-based decision aid | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Agency for Healthcare Research and Quality (AHRQ) | Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III | 01/23 | 12/26 | | |
NCT05094102: Intraoperative Evaluation of Axillary Lymphatics |
|
|
| Completed | N/A | 9 | US | OnLume Imaging System, Indocyanine green, ICG | University of Wisconsin, Madison, National Institutes of Health (NIH), OnLume Inc., National Cancer Institute (NCI) | Lymphedema, Surgery, Breast Cancer | 04/23 | 04/23 | | |
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
|
|
| Terminated | N/A | 5 | US | Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer, Breast Neoplasms | 02/24 | 02/24 | | |
NCT05609435: Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer |
|
|
| Active, not recruiting | N/A | 104 | US | REASSURE | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer | 11/25 | 11/25 | | |
COMET, NCT02926911: Comparing an Operation to Monitoring, With or Without Endocrine Therapy () Trial For Low Risk DCIS |
|
|
| Active, not recruiting | N/A | 997 | US | Surgery, Active Monitoring | Alliance Foundation Trials, LLC., Patient-Centered Outcomes Research Institute, Duke University, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, New York University, Washington University School of Medicine | DCIS, Ductal Carcinoma in Situ | 07/28 | 07/28 | | |
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma |
|
|
| Recruiting | N/A | 2998 | Europe, Canada, US, RoW | Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin | Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre | Cutaneous Melanoma, Stage II | 12/29 | 12/34 | | |
| Connect, Cancer |
NCT03096418: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
|
|
| Recruiting | 4 | 50 | US | Paclitaxel, Taxol | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Neoplasm Female | 06/26 | 06/26 | | |
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. |
|
|
| Recruiting | 3 | 260 | Europe, Canada, US, RoW | Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone | Sanofi | Chronic Graft Versus Host Disease | 09/28 | 09/28 | | |
| Terminated | 2 | 15 | US | PSMA-based 18F-DCFPyL PET tracer, PSMA | University of Wisconsin, Madison | Gynecologic Cancer | 01/20 | 01/20 | | |
SMILE, NCT04738292: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The Study) |
|
|
| Terminated | 2 | 11 | US | Onapristone, Fulvestrant, Fulvestrant Injection | University of Wisconsin, Madison, Context Therapeutics Inc. | ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer | 04/23 | 05/23 | | |
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
|
|
| Terminated | 2 | 21 | US | Bendamustine, Obinutuzumab, GA101, RO5072759 | University of Wisconsin, Madison, Genentech, Inc. | Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma | 07/23 | 07/23 | | |
| Active, not recruiting | 2 | 217 | Europe, Japan, US, RoW | tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex | Seagen Inc., Seagen, Inc. | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | 11/23 | 05/25 | | |
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy |
|
|
| Active, not recruiting | 2 | 31 | US | Sacituzumab Govitecan, IMMU-132 | University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences | Prostate Cancer | 04/24 | 04/25 | | |
| Active, not recruiting | 2 | 77 | Europe, Canada, US | SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin | Seagen Inc., Merck Sharp & Dohme LLC | Melanoma, Carcinoma, Non-Small- Cell Lung | 01/24 | 10/25 | | |
| Recruiting | 2 | 340 | Europe, US | RP1, nivolumab, Opdivo | Replimune Inc., Bristol-Myers Squibb | Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC | 12/25 | 12/28 | | |
|
|
|
| Active, not recruiting | 2 | 26 | US | Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim | University of Wisconsin, Madison, Medical College of Wisconsin | Diffuse Large B Cell Lymphoma, DLBCL, Cancer | 02/25 | 02/27 | | |
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 56 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ | Dwight Owen, Genentech, Inc. | Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 | 12/25 | 12/26 | | |
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer |
|
|
| Active, not recruiting | 2 | 232 | Europe, US, RoW | DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil | Leap Therapeutics, Inc., BeiGene | Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer | 06/25 | 12/25 | | |
|
|
|
|
|
|
|
NCT04587128: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC |
|
|
| Recruiting | 2 | 71 | US | Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab | University of Wisconsin, Madison, Doris Duke Charitable Foundation | Metastatic Colorectal Cancer | 10/25 | 10/25 | | |
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC |
|
|
| Terminated | 2 | 6 | US | IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR | ImmuneSensor Therapeutics Inc. | Oligometastatic Disease | 09/24 | 09/24 | | |
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies |
|
|
| Terminated | 2 | 16 | US | IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR | ImmuneSensor Therapeutics Inc. | Oligoprogressive | 11/24 | 11/24 | | |
NCT01743950: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab |
|
|
| Terminated | 2 | 49 | US | Bevacizumab, PRDR, re-irradiation | University of Wisconsin, Madison, Genentech, Inc., National Cancer Institute (NCI) | Glioma | 12/24 | 12/24 | | |
NCI-2019-07966, NCT04150640: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 52 | US | Nal-IRI, liposomal irinotecan, Oxaliplatin, 5-FU, Fluorouracil, Trastuzumab, Pembrolizumab, Nivolumab | University of Wisconsin, Madison, Ipsen | Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 12/25 | 12/26 | | |
NCT05988918: Multicenter Trial of ESK981 in Patients With Select Solid Tumors |
|
|
| Recruiting | 2 | 66 | US | ESK981, CEP-11981 | University of Michigan Rogel Cancer Center | Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma | 04/27 | 04/29 | | |
NCT05109494: Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas |
|
|
| Recruiting | 2 | 30 | US | Conventional Fractionated, Hypofractionated | University of Wisconsin, Madison | Soft Tissue Sarcoma | 11/26 | 11/26 | | |
MAPBI, NCT03936478: Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer |
|
|
| Recruiting | 2 | 30 | US | MRIdian Radiation Treatment Unit | University of Wisconsin, Madison | Breast Cancer, DCIS, LCIS | 01/27 | 01/31 | | |
| Active, not recruiting | 1/2 | 37 | US | Gedatolisib, Talazoparib | Kari Wisinski, Pfizer, Celcuity Inc | TNBC - Triple-Negative Breast Cancer | 07/24 | 07/24 | | |
| Recruiting | 1/2 | 37 | US | ribociclib, LEE011, Bicalutamide | Kari Wisinski, Novartis, Big Ten Cancer Research Consortium, University of Wisconsin, Madison | Triple Negative Breast Cancer | 09/25 | 09/25 | | |
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. |
|
|
| Recruiting | 1/2 | 40 | US | Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex, | Criterium, Inc., Novartis, Seagen Inc. | HER2-positive Metastatic Breast Cancer | 08/24 | 06/25 | | |
NCT04989946: Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer |
|
|
| Recruiting | 1/2 | 60 | US | Degarelix, pTVG-AR, Nivolumab, Opdivo, Cemiplimab, Libtavo, Fianlimab, REGN3767, FLT PET/CT, 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) positron emission tomography (PET) /computed tomography (CT) | University of Wisconsin, Madison, Madison Vaccines, Inc, United States Department of Defense, Regeneron Pharmaceuticals, Bristol-Myers Squibb, National Cancer Institute (NCI) | Prostate Cancer | 12/26 | 12/28 | | |
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 264 | US | [203Pb]VMT01, [212Pb]VMT01, Nivolumab | Perspective Therapeutics | Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III | 12/27 | 12/29 | | |
NCT02508038: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors |
|
|
| Recruiting | 1 | 22 | US | TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate, Zoledronic Acid, Zometa | University of Wisconsin, Madison | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma | 12/25 | 12/26 | | |
NCT03232164: PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer |
|
|
| Completed | 1 | 126 | US | 18F-DCFPyL PET | University of Wisconsin, Madison | Prostate Cancer, Prostate Neoplasm | 11/24 | 11/24 | | |
NCT06392711: Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia |
|
|
| Recruiting | 1 | 36 | US | Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1 | University of Wisconsin, Madison | Xerostomia, Graft-versus-host-disease, Sjogren's Disease | 11/28 | 11/28 | | |
NCT04174352: FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 12 | US | Tamoxifen, FES PET/CT | University of Wisconsin, Madison | ERα+ Breast Cancer, ESR1 Gene Mutation | 12/25 | 12/26 | | |
| Active, not recruiting | 1 | 52 | US | CUE-102 | Cue Biopharma | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 12/24 | 12/26 | | |
NCT04020276: OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases |
|
|
| Suspended | 1 | 48 | US | SBRT | University of Wisconsin, Madison | Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment | 02/25 | 02/25 | | |
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy |
|
|
| Recruiting | 1 | 34 | US | Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem | Norman J. Lacayo, Gateway for Cancer Research | Acute Myeloid Leukemia | 03/26 | 03/26 | | |
NCT05568680: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma |
|
|
| Recruiting | 1 | 42 | US | SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR | Verismo Therapeutics | Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant | 12/27 | 12/27 | | |
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations |
|
|
| Active, not recruiting | 1 | 54 | Europe, US, RoW | KIN-3248 | Kinnate Biopharma | Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma | 06/26 | 09/26 | | |
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies |
|
|
| Recruiting | 1 | 33 | US | Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV | Medical College of Wisconsin | B-cell Lymphoma, Burkitt Lymphoma | 05/26 | 05/26 | | |
NCT05477823: Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer |
|
|
| Recruiting | 1 | 30 | US | External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI) | University of Wisconsin, Madison | Prostate Cancer | 08/27 | 08/27 | | |
NCT05820711: Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy |
|
|
| Recruiting | 1 | 30 | US | MSC | University of Wisconsin, Madison, National Institute of Dental and Craniofacial Research (NIDCR) | Head and Neck Cancer, Xerostomia | 03/26 | 03/26 | | |
| Recruiting | 1 | 120 | Japan, US, RoW | EO-3021 | Elevation Oncology | Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms | 09/28 | 12/28 | | |
NCT05132478: The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer |
|
|
| Completed | N/A | 126 | US | Emotionally Supportive Video, Standard Video | University of Wisconsin, Madison, National Cancer Institute (NCI), University of Michigan | Thyroid Cancer, Thyroid Nodule, Benign Thyroid Nodule | 02/23 | 02/23 | | |
NCT05094102: Intraoperative Evaluation of Axillary Lymphatics |
|
|
| Completed | N/A | 9 | US | OnLume Imaging System, Indocyanine green, ICG | University of Wisconsin, Madison, National Institutes of Health (NIH), OnLume Inc., National Cancer Institute (NCI) | Lymphedema, Surgery, Breast Cancer | 04/23 | 04/23 | | |
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
|
|
| Terminated | N/A | 5 | US | Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer, Breast Neoplasms | 02/24 | 02/24 | | |
NCT05647564: PET/CT Characterization of Treatment Resistance |
|
|
| Recruiting | N/A | 20 | US | F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET) | University of Wisconsin, Madison | Prostate Cancer | 03/25 | 03/27 | | |
NCT06701201: A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product |
|
|
| Not yet recruiting | N/A | 60 | US | SynKIR-110, SynKIR-310 | Verismo Therapeutics | Cancer | 02/42 | 02/42 | | |
NCT06608511: Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers |
|
|
| Recruiting | N/A | 20 | US | Blood draw for the laboratory assessment | University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS) | Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin, Site Unspecified, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin | 12/26 | 12/26 | | |
| Recruiting | N/A | 30 | US | IONA Mind app | University of Wisconsin, Madison, National Cancer Institute (NCI) | Head and Neck Cancer, Head and Neck Cancers, Depression | 07/25 | 07/25 | | |
NCT05609435: Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer |
|
|
| Active, not recruiting | N/A | 104 | US | REASSURE | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer | 11/25 | 11/25 | | |
| Recruiting | N/A | 5000 | US | PMMTB (Precision Medicine Molecular Tumor Board) | University of Wisconsin, Madison, National Cancer Institute (NCI) | Hematologic Neoplasms, Solid Neoplasm | 03/27 | 03/27 | | |
NCT05175092: Living Donor Liver Transplantation for CRC Liver Metastases |
|
|
| Withdrawn | N/A | 50 | US | Living Donor Liver Transplantation, LDLT | University of Wisconsin, Madison | Liver Metastasis Colon Cancer | 12/30 | 12/30 | | |
